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Patients who are at risk for cerebrovascular disease and those who have had a recent ischemic stroke are treated with a variety of drugs. Some of these drugs impair recovery of function after experimental focal brain injury in laboratory animals. In order to test the hypothesis that these drugs may also have detrimental effects in man and to determine the feasibility of a prospective study, a retrospective analysis of 58 patients with carotid distribution strokes who were enrolled in a prospective cohort study of stroke outcome were analyzed. Sensorimotor function was measured by observers blind to the study hypothesis shortly after stroke and again 5 and 30 days later with the Fugl-Meyer assessment. Independence in activities of daily living was measured with the Barthel Index. Patients were subsequently divided into two groups based on the drugs received either immediately before the onset of neurologic symptoms or during the subsequent hospitalization. Patients receiving phenytoin, benzodiazepines (triazolam, chlodiazepoxide, or alprazolam), neuroleptics (chlorpromazine,prochlorperazine,orhaloperidol), or the antihypertensive drugs, clonidine or prazosin, constituted the "detrimental drug" group (n = 24). Patients receiving other medications formed the "neutral drug" group (n = 34). The two groups of patients were similar with respect to stroke risk factors, prognostic factors, and initial functional deficits. Compared to patients in the "neutral drug" group, patients in the "detrimental drug" group had poorer sensorimotor function (Mann-Whitney U = 157, Z = -2.04; p = 0.04) and were less independent in activities of daily living (Mann-Whitney U = 139, Z = -2.368; p = 0.02) 30 days after the stroke. "Detrimental drug" group patients also had slower overall 30-day recoveries (Mann-Whitney U = 154, Z = -2.89; p = 0.004). A secondary multivariate analysis indicated that the calculated recovery rate was significantly related to the patient's initial level of consciousness, initial Fugl-Meyer score, study drug group, and race (i.e., the overall 30-day recovery was significantly related to study drug group independent of the severity of the initial deficit). These data are consistent with the hypothesis that specific drugs taken by patients with cerebral infarction may influence their subsequent functional recoveries. Until the emerging pharmacology of functional recovery is better understood, care should be taken in the selection of drugs used in the treatment of patients with cerebrovascular disease. Key Words: Stroke&mdash;Cerebral infarc-tion&mdash;Functional recovery&mdash;Rehabilitation&mdash;Drugs&mdash;Fugl&mdash;Meyer assessment.
Recovery after stroke is influenced by a variety of biologic and environmental factors. Patient age, lesion size and location, prior stroke, initial functional status, and various social characteristics may impact on functional outcome (1) . In addition, studies in laboratory animals suggest that certain drugs may facilitate recovery following brain injury, whereas other drugs may interfere with the recovery process (2) . Even a single dose of these drugs given shortly after brain injury can have a profound impact on recovery. Effects may be found over the first few hours following drug administration. For example, treatment with d-amphetamine enhances motor recovery in rats and cats following unilateral injury to the sensorimotor cortex (3) (4) (5) (6) (7) (8) (9) (10) (11) . Drugs that impair recovery of sensorimotor function in laboratory animal studies include phenytoin (12) , diazepam (13) , haloperidol (3, 5, 14, 15) , prazosin (16, 17) , and clonidine (16) (17) (18) .
Many of these drugs are commonly taken by patients with stroke (19).
It is not yet known whether drugs that affect recovery of function in laboratory animals have similar effects in humans. Yet, the possibility that recovery after stroke may be influenced by drugs currently prescribed for patients has important clinical implications. We hypothesized that stroke patients who received one or more of the drugs that impair recovery in laboratory animal studies would have greater initial functional deficits and recover function slower than patients who did not receive one of these drugs. To test this hypothesis, we studied the recoveries of a cohort of patients who presented with an acute ischemic stroke in the distribution of the carotid artery.
In analogy to the studies in laboratory animals with focal brain injury, the Fugl-Meyer assessment of sensorimotor performance was used as the primary outcome measure (20) . This scale measures selective and synergistic movements and has both concurrent and predictive validity (20) and high inter-and intratester reliability (21) . Although sensorimotor performance as measured by the Fugl-Meyer assessment is an important indicator of functional ability, it does not provide a direct measure of independence in activities of daily living. Accordingly, the Barthel Index (22) was employed as a secondary outcome measure. This scale has been used extensively to measure outcome following stroke and is correlated with other measures of functional status (23, 24) .
Methods

Patients
This analysis was carried out retrospectively using a subset of patients enrolled in the ongoing Durham County Stroke Study. The Durham County Stroke Study is a prospective cohort study designed to investigate the impact of a variety of prognostic factors on stroke outcome. All patients with an acute ischemic stroke presenting to the three acute care hospitals in Durham County, North Carolina, were screened for participation in the study. These hospitals are Duke Medical Center (a tertiary care teaching hospital), the Durham Veterans Administration Hospital, and Durham County General Hospital (a secondary care community hospital). These three hospitals care for virtually every patient with acute stroke in Durham County. The study protocol was approved by the Institutional Review Boards of each hospital.
Patients invited to participate in the Durham County Stroke Study were over 40 years of age, resided within 100 miles of the hospital, were admitted to the hospital within 24 h of the onset of neurologic symptoms, underwent head computed tomography or magnetic resonance imaging, and had a clinical course consistent with the diagnosis of ischemic stroke. Patients were excluded from the study if they had a pre-existing motor deficit that affected the assessment of the new stroke, if the new deficit resolved within 24 h, if they had a co-existing condition with likely early mortality (i.e., metastatic systemic cancer), or if they had an acute myocardial infarction or severe congestive heart failure at the time of hospital admission.
Patients included in the present analysis were those who met the eligibility requirements and had agreed to participate in the Durham County Stroke Study, had an acute ischemic stroke in the distribution of the carotid artery between March 1987 and May 1988, and had been followed for at least 30 days after the stroke.
Patient Characteristics and Functional
Assessment A trained nurse-clinician or physician's assistant who was unaware of the study hypothesis gathered prospective data from the medical record, direct patient interview, and physical examination. The patients' age, gender, race, and history of hypertension, cigarette smoking, diabetes, cardiac disease, and prior stroke were recorded. The patients' level of consciousness at the time of admission was recorded on a six-point scale (25): 0, normal; 1, drowsy, not confused ; 2, drowsy, confused, but arouses to verbal commands; 3, does not arouse to verbal commands, but has adaptive responses to pain; 4, has reflex responses to pain; and 5, no response to pain. The involved hemisphere, presence of aphasia, and 30-day mortality were also recorded. Mean arterial blood pressure at the time of admission was calculated for each patient [diastolic pressure + 0.67 X (systolic pressure -diastolic pressure)].
Sensorimotor function was measured with the Fugl-Meyer assessment at the time of admission (within 48 h), 5 days and 30 days after the stroke. Scores on this 226-point scale (20) were adjusted to account for items that could not be tested in individual patients (e.g., due to limb amputation, intravenous or intraarterial lines, severe joint disease, bed rest restrictions ; Adjusted Score = Raw Score X [226/(226 -Points Not Testable)]. The Barthel Index (22) was obtained 5 and 30 days after the stroke. All functional assessments were performed by observers blind to the study hypothesis.
If the patient had been discharged from the hospital, follow-up evaluations were carried out in the patient's residence.
Drug Use and Patient Classification
A retrospective chart review was carried out for all patients who met inclusion criteria for the present analysis. Data were recorded without knowledge of the patients' recovery status or Fugl-Meyer scores.
Medications on admission (i.e., at the time of the stroke) were determined by review of medical student, intern, resident, attending physician, and nursing notes. Subsequent drug use during the acute hospitalization was determined by examination of nursing medication sheets and hospital pharmacy records.
For the purpose of the present analysis, patients were then divided into two groups depending solely on their drug use at the time of the stroke and during the subsequent hospitalization. Patients in the &dquo;detrimental drug&dquo; group had taken one or a combination of the drugs that, based on the laboratory animal data, were hypothesized to impair recovery. These drugs were the anticonvulsant phenytoin, benzodiazepines (triazolam, chlodiazepoxide, or alprazolam), neuroleptics (chlorpromazine, prochlorperazine, or haloperidol), and the antihypertensives, clonidine HCI and prazosin HCI. The remaining patients, all of whom received at least one medication, formed the &dquo;neutral drug&dquo; group. These medications have not been investigated in the laboratory with respect to their effects on recovery.
Statistical Analysis
In order to determine the comparability of the study groups, categoric variables were compared with the Chi-square test, ordinal variables with the
Mann-Whitney U test, and continuous variables with
Student's t test.
Scores obtained with the Fugl-Meyer assessment do not satisfy the requirements for analysis with parametric statistics. Accordingly, the median-adjusted Fugl-Meyer scores of the two patient groups were compared at the time of admission, 5 and 30 days after the stroke with the Mann-Whitney U test. In order to compare the rates of improvement between the two groups, the trapezoidal rule (26) was used to calculate the areas under the curves formed when each patient's adjusted Fugl-Meyer score was plotted as a function of time after stroke [i.e., area under the timeeffect curve (27) ]. The median recovery rates for the two groups of patients were then compared with the Mann-Whitney U test (28) . The Mann-Whitney U test was also used to compare the median Barthel Index between the two groups of patients 5 and 30 days after the stroke. Spearman Rank Correlation Coefficient was used to determine the overall relationship between the adjusted Fugl-Meyer score and the Barthel Index. A secondary multivariate regression analysis was used to assess the relative importance of potential prognostic factors on recovery rate.
Results
Between March 1987 and May 1988, 781 patients were screened for participation in the Durham County Stroke Study. Seventeen patients were under 40 years of age, 38 resided more than 100 miles from the hospital, 137 presented to the hospital more than 24 h after the onset of symptoms, 158 had intracerebral hemorrhage or another condition making the stroke diagnosis uncertain, 170 had a pre-existing motor deficit that interfered with the assessment of the new stroke, 88 had a deficit that resolved in less than 24 h, 32 had a co-existing condition with likely early mortality, 15 had acute myocardial infarction or severe congestive heart failure, and 26 patients refused to participate in the study. Twenty-one patients had multiple reasons for exclusion. Of the remaining 79 patients, 3 did not have baseline Fugl-Meyer assessments performed, and 18 had strokes in uncertain vascular distributions or in the distribution of the vertebral or basilar arteries. Thus, 58 patients served as the cohort for the present analysis. Table 1 gives the drugs used by patients in the study cohort. In agreement with a previous study (19) , all of the patients had been treated with multiple drugs. Twenty-four patients had received one or a combination of the drugs hypothesized to impair sensorimotor recovery after stroke (&dquo;detrimental drug&dquo; group); Table 1 . Drugs administered to patielltSZ ' The number of patients in each group who had received the indicated drugs is shown. specific drugs are given in the text. five patients had received two of these drugs, and one patient had received three. Nine patients were taking a &dquo;detrimental drug&dquo; at the time of the stroke; 15 patients were given at least one &dquo;detrimental drug&dquo; during the subsequent hospitalization. Thirty-four pa-tients had not received any of these drugs at the time of the stroke or during the subsequent hospitalization (&dquo;neutral drug&dquo; group).
The two groups of patients were comparable with respect to a variety of cerebrovascular risk and prognostic factors as given in There was a strong, significant correlation between the adjusted Fugl-Meyer score and the Barthel Index 5 days (Spearman r = 0.76, Z = 5.47; p < 0.0001) and 30 days (Spearman r = 0.89, Z = 5.91; p < 0.0001) after the stroke. Thus, the data provide evidence of the criteria validity (predictive and concurrent) (29) of the adjusted Fugl-Meyer assessment.
The median adjusted Fugl-Meyer scores for both groups of patients at the time of admission, 5 days and 30 days after the stroke, are given in Fig. 1 . The difference between the groups at the time of admission was not statistically significant (&dquo;detrimental drug&dquo; group, n = 24, &dquo;neutral drug&dquo; group, n = 34; Mann-Whitney U = 312.5, Z = -1.51; p = 0.131). &dquo;Detri- Abbreviations: Hx HTN, history of hypertension; Hx smoke, history of cigarette smoking; Hx diabetes, history of diabetes; Hx CAD, history of coronary heart disease; prior CVA, history of prior stroke; median LOC, level of consciousness at presentation-graded on six-point scale, as described in the text; MAP, mean arterial blood pressure at presentation. mental drug&dquo; group patients (n = 22) had significantly lower scores than &dquo;neutral drug&dquo; group patients (n = 32) 5 days after the stroke (Mann-Whitney U = 239.5, Z = -1.98; p = 0.048). One patient in the &dquo;neutral drug&dquo; group had died by the time of the 5day evaluation; two patients in the &dquo;detrimental drug&dquo; group and an additional one patient in the &dquo;neutral drug&dquo; group did not have 5-day Fugl-Meyer assessments performed. Thirty days after the stroke, &dquo;detrimental drug&dquo; group patients (n = 17) still had significantly lower scores as compared to &dquo;neutral drug&dquo; group patients (n = 29) (Mann-Whitney U = 157, ' Z = -2.04; p = 0.041). Three patients in the &dquo;detrimental drug&dquo; group and three patients in the &dquo;neutral drug&dquo; group died between the 5-and 30-day evaluations ; four patients in the &dquo;detrimental drug&dquo; group and a single patient in the &dquo;neutral drug&dquo; group did not have the 30-day Fugl-Meyer assessments per-formed. Overall, &dquo;detrimental drug&dquo; group patients recovered sensorimotor function more slowly than &dquo;neutral drug&dquo; group patients (Mann-Whitney Us 154, Z = --2.89; p = 0.004).
Five days after the stroke, the median Barthel Index for &dquo;detrimental drug&dquo; group patients was lower than that for &dquo;neutral drug&dquo; group patients, but the difference was not statistically significant (median Barthel Index for &dquo;detrimental drug&dquo; group patients = 15; median Barthel Index for &dquo;neutral drug&dquo; group patients = 50; Mann-Whitney U = 284.5, Z = -1.12; p = 0.263). However, the median Barthel Index for &dquo;detrimental drug&dquo; group patients was significantly lower than for &dquo;neutral drug&dquo; group patients 30 days after the stroke (median Barthel Index for &dquo;detrimental drug&dquo; group patients = 55; median Barthel Index for &dquo;neutral drug&dquo; group patients = 95; Mann-Whitney U = 139, Z = -2.368; p = 0.018). Table 3 . Multivariate analysis of pote11tial prog11ostic factors with calculated recovery rates in tlte 49 patients Hot taking &dquo;detrimental drugs&dquo; at the time of onset of neurologic synrpfoms°& dquo;'Detrimental drug&dquo; group patients were coded as &dquo;0&dquo;; patients in the &dquo;neutral drug&dquo; group were coded as &dquo;1.&dquo; Race was coded as 0 = whites, 1 = nonwhites.
The involved cerebral hemisphere was coded as 0 = left, 1 = right. A history of prior stroke, hypertension, diabetes, cigarette smoking, or coronary artery disease was coded as 0 = absent, 1 = present. Aphasia was coded as 0 = absent, 1 = present. Males were coded as &dquo;0&dquo;; females were coded as &dquo;1.&dquo; The LOC code is given in the text. Abbreviations are as given in the legend for Table 2 .
Despite the small numbers of patients in the &dquo;detrimental drug&dquo; group, recovery of the nine patients taking &dquo;detrimental&dquo; drugs at the time of onset of neurologic symptoms was analyzed separately from the 15 patients who received a &dquo;detrimental drug&dquo; during the hospitalization following stroke. There were no differences in the median-admission-adjusted Fugl-Meyer scores (Mann-Whitney U = 52.5, Z = 0.899; p = 0.37), 30-day adjusted Fugl-Meyer scores (Mann-Whitney U = 28.5, Z = -0.722; p = 0.47), recovery rates (Mann-Whitney U = 42, Z = 0.46; p = 0.64), or 30-day Barthel Indices (Mann-Whitney U = 25, Z = -1.07; p = 0.28) between these subgroups. The nine patients who had been taking a &dquo;detrimental drug&dquo; at the time of onset of neurologic symptoms had a lower admission-median-adjusted Fugl-Meyer score than the 49 patients who had not received one of these drugs (median-adjusted Fugl-Meyer score = 82 and 117, respectively), but the difference was not significant (Mann-Whitney U = 148, Z = -1.558; p = 0.12).
A secondary multivariate analysis was carried out with the calculated recovery rate as the dependent variable and potential prognostic factors as independent variables in the same 49 patients who had not received a &dquo;detrimental drug&dquo; at the time of the onset of neurologic symptoms (Table 3 , r = 0.866, df = 14; p = 0.0004). This analysis takes into account the initial difference between the groups with respect to the &dquo;severity&dquo; of the stroke (as measured by the initial level of consciousness and initial-adjusted Fugl-Meyer scores) and eliminates the potential contribution of &dquo;detrimental drugs&dquo; taken at the time of the stroke to the initial deficit (i.e., the analysis includes only the 15 patients who received a potentially &dquo;detrimental drug&dquo; during the course of the hospitalization and the 34 patients who received &dquo;neutral drugs''). Table 3 gives the standard beta coefficients and the associated probabilites for each independent variable. The initial level of consciousness, initial-adjusted Fugl-Meyer score, &dquo;drug group;' and race contributed significantly to the variance in the dependent variable.
Discussion
The results of the present analysis are consistent with the study hypothesis and suggest that drugs taken by patients at the time of or soon after a cerebral infarction may influence their subsequent functional recoveries. Thirty days after the stroke, patients receiving &dquo;detrimental drugs&dquo; had significantly poorer sensorimotor function (adjusted Fugl-Meyer score) and were less independent in activities of daily living (Barthel Index) than a comparable group of patients who did not receive one of these drugs.
Animal studies suggest that the first few hours after brain injury is an important window of time in which to pharmacologically influence the neurologic deficit and its subsequent recovery. These studies indicate that drugs may affect neurologic function within hours of administration. Even a single dose of a drug given in the peri-infarct period can have a profound impact on recovery. Therefore, it was hypothesized that &dquo;detrimental drug&dquo; group patients would have greater initial deficits than patients not taking one of these drugs. In fact, patients who had been taking a &dquo;detrimental drug&dquo; at the time of stroke did have a greater initial deficit, but the difference was not statistically significant. This lack of statistical significance may be due to the relatively small number of patients in each of the study groups (i.e., Type II error). Regardless of drug group, the patients' motor function soon after hospital admission was an important pre-dictor of functional outcome, in agreement with previous reports (1, 30, 31) . Thus, the lower initial scores in &dquo;detrimental drug&dquo; group patients influenced the overall 30-day recovery. However, the multivariate analysis also provided the central finding in this study; the overall 30-day recovery was significantly related to study drug group independent of the severity of the initial deficit.
The present study must be interpreted with caution. Care was taken to obtain functional assessments by observers blind to the study hypothesis. Furthermore, medication use was determined without knowledge of the patients' recovery status. Fortunately, the two groups were equivalent for all of the characteristics that could be measured. But, the present analysis was performed retrospectively. Actual drug use at the time of stroke was determined by patient report as recorded in the hospital chart and could be unreliable. The clinical indication for the use of a specific drug in an individual patient could not be accurately determined. Potentially important covariates such as medical co-morbidity, the presence of mood disorders (32, 33) , and the availability of a caring spouse or caretaker (31, 34) were not recorded. Finally, the small number of patients precluded analyses of individual drug effects or dose-effect relationships. The present study provides evidence that studies of recovery from brain injury in laboratory animals may be predictive of drug effects in humans. Other studies have also reported such correlations. In a small, prospective, double-blind trial, amphetamine was found to facilitate short-term motor recovery after stroke in man (35) . Haloperidol may interfere with recovery from aphasia after stroke (2) . If investigations in laboratory animals prove relevant to humans, they may provide a tool for the development of drugs with the potential to enhance functional recovery. Other drugs that are commonly administered after stroke or brain injury (19) could be screened in the laboratory for potential harmful effects on the recovery process. Until a prospective study can be carried out, the results of this study urge care in the selection of drugs used in the treatment of patients after stroke.
